Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.35 |
| ▸ | S100A4 | P26447 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NSD2 | O96028 | 2/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.33 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.33 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16556014 | 0.79 | ACHE (0.41) | ACHEAADATCYP19A1METAP1 | |
| SCHEMBL28725626 | 0.78 | CYP19A1 (0.54) | ACHEMAPTCYP19A1TP53RECQL | |
| SCHEMBL28725627 | 0.78 | CYP19A1 (0.54) | ACHEMAPTCYP19A1TP53RECQL | |
| SCHEMBL1453411 | 0.78 | ACHE (0.66) | ACHEAADATNOTUMMAPK14S100A4 | |
| SCHEMBL19764906 | 0.78 | CDK5 (0.44) | ACHES100A4CYP19A1METAP1 | |
| SCHEMBL8558933 | 0.78 | ACHE (0.40) | ACHEAADATNOTUMMAPK14S100A4 | |
| SCHEMBL30666419 | 0.78 | ACHE (0.40) | ACHEAADATNOTUMMAPK14S100A4 | |
| SCHEMBL5952927 | 0.77 | METAP1 (0.37) | ACHEAADATNOTUMMAPK14S100A4 | |
| SCHEMBL5951729 | 0.74 | CYP19A1 (0.45) | ACHES100A4MAPTBCHECYP19A1 | |
| SCHEMBL5952358 | 0.74 | ACHE (0.40) | ACHEAADATNOTUMMAPK14S100A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590062-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| EP-4026835-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-4026835-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-10-21 | — | — | US | disclosed |
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-10-21 | — | — | US | disclosed |
| CN-110799509-A | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2020-02-14 | — | — | CN | disclosed |
| US-20180305315-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2018-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | CD274, PDCD1, PDCD1LG2 | ACHE 3876/4885AADAT 3923/4885NOTUM 3868/4885 |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | CD274, PDCD1LG2, PDCD1 | ACHE 4256/4885AADAT 4344/4885NOTUM 4444/4885 |
| US-20180305315-A1 | PD-1/PD-L1 INHIBITORS | CD274, PDCD1, PDCD1LG2 | ACHE 3876/4885AADAT 3923/4885NOTUM 3868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.